Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frespaciguat Single Dose in Pulmonary Arterial Hypertension
NCT03744637Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of frespaciguat in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced at Least 1 Adverse Event at 32 weeks, Number of Participants Who Discontinued From the Study Due to an AE at 32 weeks and 1 more. Started Jan 2019; status: completed.
02
Drugs
frespaciguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03744637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744637.